NCT06372886Completed
Clinical Outcomes of Preservation Versus Resection of Portal/Superior Mesenteric Vein During Pancreaticoduodenectomy in Pancreatic Cancer Patients Who Respond to Neoadjuvant Treatment
Source: ClinicalTrials.gov · Last updated 18 Apr 2024
Brief summary (registry, in English)
1. There is a lack of evidence on the need to perform portal/superior mesenteric vein (PV/SMV) resection routinely in pancreatic ductal adenocarcinoma (PDAC) patients with venous involvement who responded to neoadjuvant treatment (NAT). 2. There is no significant differences in R0 rate, 5-year overall survival and recurrence-free survival between the PV/SMV preservation (PVP) group and PV/SMV resection (PVR) group. 3. PVP group showed significantly better 5-year PV/SMV stenosis free survival than the PVR group. 4. We propose that if dissection is possible and there is a high likelihood of achieving R0 resection after NAT, routine PVR may be unnecessary in PDAC patients with venous involvement.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 264 (actual)
- First submitted
- 8 Apr 2024
- Start date
- 1 Jan 2012
- Primary completion date
- 1 Jan 2022
- Lead sponsor
- Seoul National University Hospital
- Diseases
- Pancreatic cancer, Childhood cancers
- NCT number
- NCT06372886
What you commit to
- Study type: Observational
- Participants enrolled: 264
- From 1 Jan 2012 to the primary completion date, 1 Jan 2022
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who underwent palliative surgery
- Patients who death within 30 days of surgery
- Patients who underwent resection for suspected main artery and adjacent organ invasion
Other illness
- Metastatic unresectable and locally advanced pancreatic cancer
- Resectable pancreatic cancer without portal/superior mesenteric vein invasion
- Cancer aggravation after neoadjuvant treatment
Other
- Portal/superior mesenteric vein encasing and narrowing after neoadjuvant treatment
- Non-pancreatic ductal adenocarcinoma patients
- Loss of follow-up patients
Who the study is looking for
- Pancreatic head cancer patients who underwent surgery after neoadjuvant treatment between January 2012 and December 2022 at Seoul National University Hospital
Age in the registry: - to 79 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.